53.63 USD
↘ 2.77 (4.90%)LIVE (AS OF 02:54 PM EDT)
Kiniksa Pharmaceuticals International, plc Class A Ordinary Shares
KNSANASDAQ • USD
Market: OPEN
Open?$56.95
High?$57.40
Low?$53.46
Prev. Close?$56.51
Volume?305.3K
Avg. Volume?782.9K
VWAP?$54.55
Rel. Volume?0.39x
Bid / Ask
Bid?$46.37 × 100
Ask?$61.94 × 100
Spread?$15.57
Midpoint?$54.16
Valuation & Ratios
Market Cap?4.3B
Shares Out?46.3M
Float?38.9M
Float %?84.2%
P/E Ratio?59.51
P/B Ratio?7.18
EPS?$0.95
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.
Address
105 PICCADILLY, SECOND FLOOR
LONDON, W1J 7NJ
Phone: (781) 431-9100
LONDON, W1J 7NJ
Phone: (781) 431-9100
Technical Outlook
Loading...
Fundamental Outlook
Loading...
Short Interest
Loading...
Financial Health
Current Ratio?3.79Strong
Quick Ratio?3.33Strong
Cash Ratio?1.21Strong
Debt/Equity?0.12Low
ValuationFAIRLY VALUED
Score56/100
P/E?59.5PRICEY▾
P/B?7.18FAIR▾
P/S?5.77FAIR▾
P/FCF?26.5FAIR▾
EV/EBITDA?44.6HIGH▾
EV/Sales?5.61FAIR▾
Returns & Efficiency
ROE?12.1%STRONG▾
ROA?8.9%STRONG▾
Cash Flow & Enterprise
FCF?$164.2M
Enterprise Value?$4.2B
Fundamentals ratios updated end of day